News and Trends 10 Oct 2016 The CRISPR Revolution is here, but how can we make it Useful? By this point, you can’t have escaped hearing about CRISPR. First discovered in the 1980’s, the repeated sequences and their function in bacterial defense systems remained a mystery until almost 10 years ago, when it was hailed as the biggest scientific discovery of the century. Since then, scientists have leveraged the adaptable, heritable mechanism to develop the most powerful gene-editing technology […] October 10, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Meet the French CEO who wants to Break Barriers to Drug Delivery The objective of the French biotechnology company, Vect-Horus, is to leverage its technology, VECTrans, to facilitate the delivery of drugs into the brain and other organs. For this innovation, the company recently received the Frost & Sullivan 2016 Leadership award, which independently recognizes companies for demonstrating excellence in developing innovative technologies and practices within an industry. […] October 10, 2016 - 5 minutesmins - By Marie Godar Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2016 Microbial Donuts at the Vienna Design Week, fancy a bite? Here’s the Recipe! This week’s bioartist has a very sweet exhibition at the Vienna Design Week. Taylor Caputo has traveled from the other side of the pond to showcase her current project: custom donuts engineered with synthetic biology. Six talented artists are showing their work at Possible Tomorrows, an exhibition at the Vienna Design Week that combines art with Biotech and SynBio to experiment […] October 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2016 Do we hear a Tinnitus Cure? This techno-loving CEO might have one… It’s Friday, and here in Berlin, we’re ready for the club. A German company, Sonormed, is developing an app that can reduce the consequent ringing in our ears. Sonormed’s co-founder and CEO, Jörg Land, loves techno, and he started a company to help his fellow beat lovers with their common affliction of tinnitus. His soon-to-be […] October 7, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2016 Meet the ‘Haut-Couturiers’ of Bioengineering It’s time to ride the slopes and land in the French alpine capital, Grenoble, to meet our Biotech of the week, BGene Genetics. This start-up is changing the bug factory sector! BGene has developed a method to edit the chromosomes of a bug to produce proteins rather than inserting a plasmid, and this proprietary technology […] October 7, 2016 - 3 minutesmins - By Jerome Topsent Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2016 Will SynBio replace the French Wine Industry? Ava Winery is creating cheap, sustainable and customizable wine without grapes, yeast or fermentation. The company plans to commercialize its first product in the coming months, will they be able to steal customers from the most famous French wine companies? Ava Winery claims that 90% of tasters cannot tell its prototype apart from traditional wine. The […] October 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 NASH Maverick continues Rampage with €34M Cash Injection Genfit just added €34M to its cash pile through private placement to bankroll the development of its succeeding lead candidate, Elafibranor. Genfit has had a good year. Earlier this year, the company enrolled its first patient in Phase III clinical trails for Non-Alcoholic Stato-Hepatitis (NASH), and last month, it launched a new non-invasive diagnostic program. It’s […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 New UK Hero Will Fight Against Non-Small Cell Lung Cancer Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […] October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 A new Immuno-Oncology biotech’s Small Molecule hits the Clinic Since we interviewed Karus Therapeutics last year, the company has come quite a way! The Oxford-based biotech has just sent its first drug to the clinic. We first met Karus Therapeutics a year ago to talk about their small molecule therapies for cancer and inflammatory disease. The company has entered the immuno-oncology fray and is developing a […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Link found between the Microbiome and “Genetic Obesity” Researchers at King’s College London have found a new link between gut microbiome diversity (or, more specifically, the lack of it) and a particularly troubling kind of obesity. This finding could also help explain the inheritability of this disease. The explosive growth of the Microbiome field promises a whole new type of therapies, but this […] October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email